LATAM Focus Pint Pharma targets the Latin American region with a portfolio built around cancer, rare diseases and unmet medical needs, presenting frequent partner and license opportunities for late-stage or registered therapies in Brazil, Argentina, Colombia, Chile, Peru, and Ecuador.

Strategic Partnerships Active collaboration history with global biopharma companies (PharmaEssentia, BioCryst, Amicus, Onconova, Investor Awareness) indicates a strong appetite for exclusive registrations and promotion agreements that can be leveraged to accelerate market entry for new assets.

Licensing Potential Recent and past licensing deals for therapies in hematology and oncology suggest Pint Pharma is a viable channel partner for registering and promoting high-value assets in LATAM, including rare disease and cancer indications.

Financial Scale Reported revenue in the 100–250 million USD range coupled with a mid-size employee base signals a capable platform for regional commercialization, distribution, and payer engagement without requiring a full global launch team.

Geographic Reach Operations across multiple LATAM countries plus a Europe-based headquarters provide a diversified footprint for regional market access strategies, local regulatory navigation, and tailored market access discussions with payers and health authorities.